These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors. Roberts PL. Biologicals; 2014 Jul; 42(4):184-90. PubMed ID: 24981392 [Abstract] [Full Text] [Related]
6. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions. Roberts PL, Feldman P, Crombie D, Walker C, Lowery K. Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418 [Abstract] [Full Text] [Related]
7. Chromatographic removal of viruses from plasma derivatives. Burnouf T. Dev Biol Stand; 1993 Mar; 81():199-209. PubMed ID: 8174804 [Abstract] [Full Text] [Related]
8. Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography. Feldman PA, Bradbury PI, Williams JD, Sims GE, McPhee JW, Pinnell MA, Harris L, Crombie GI, Evans DR. Blood Coagul Fibrinolysis; 1994 Dec; 5(6):939-48. PubMed ID: 7893930 [Abstract] [Full Text] [Related]
10. Affinity chromatography to remove viruses during preparation of plasma derivatives. Lawrence JE. Dev Biol Stand; 1993 Dec; 81():191-7. PubMed ID: 8174803 [Abstract] [Full Text] [Related]
11. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Roberts P. Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053 [Abstract] [Full Text] [Related]
13. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate. Hilfenhaus J, Nowak T. Vox Sang; 1994 Mar; 67 Suppl 1():62-6. PubMed ID: 8091740 [Abstract] [Full Text] [Related]
14. Homologous human blood protein separation using immobilized metal affinity chromatography: protein C separation from prothrombin with application to the separation of factor IX and prothrombin. Wu H, Bruley DF. Biotechnol Prog; 1999 Mar; 15(5):928-31. PubMed ID: 10514264 [Abstract] [Full Text] [Related]
16. [Improvement in anti-hemophilic preparations and its problems. 2. Inadequacy of the heat treatment of factor concentrates on the inactivation of non-A, non-B hepatitis virus]. Inagaki M, Osano M. Rinsho Ketsueki; 1988 May; 29(5):635-9. PubMed ID: 3145994 [No Abstract] [Full Text] [Related]
17. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. Kim IS, Choi YW, Kang Y, Sung HM, Shin JS. J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304 [Abstract] [Full Text] [Related]
19. Viral safety of a new highly purified factor VIII (OCTATE). Biesert L, Lemon S, Goudeau A, Suhartono H, Wang L, Brede HD. J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169 [Abstract] [Full Text] [Related]
20. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation. Nowak T, Niedrig M, Bernhardt D, Hilfenhaus J. Dev Biol Stand; 1993 Apr; 81():169-76. PubMed ID: 8174799 [Abstract] [Full Text] [Related] Page: [Next] [New Search]